The global antacids market is on track for substantial expansion, with projections indicating a rise from USD 6,971.2 million in 2023 to an impressive USD 11,194.8 million by 2033, reflecting a robust Compound Annual Growth Rate (CAGR) of 4.9%. This growth is driven by increasing rates of gastrointestinal disorders, including heartburn and gastroesophageal reflux disease (GERD), alongside rising consumer preference for over-the-counter (OTC) remedies.
A recent report by Future Market Insights highlights the dominant role of proton pump inhibitors (PPIs) in the market, holding a significant share of 25.8% in 2022. PPIs continue to lead as the preferred treatment option for acid-related digestive issues, benefiting from their proven efficacy and growing consumer demand for effective OTC treatments.
As more individuals turn to self-medication for relief from common digestive complaints, the antacids market is witnessing a surge in demand for convenient, easily accessible digestive health solutions. This trend underscores the growing consumer focus on proactive health management and the increasing willingness to treat conditions like heartburn and GERD without a prescription.
With this steady market growth, companies in the antacids sector are expected to continue innovating, meeting the evolving needs of a health-conscious, self-medicated population. The future of the market is bright, with significant opportunities for expansion driven by both technological advancements and changing consumer behaviors in digestive health management.
Key Takeaways: Antacids Market Outlook
- Market Growth: The global antacids market is expected to grow from USD 6,646.9 million in 2022 to USD 6,971.2 million in 2023, and is projected to reach USD 11,194.8 million by 2033, with a compound annual growth rate (CAGR) of 4.9% from 2023 to 2033.
- Dominant Markets:
- The United States holds the largest share, accounting for 1% of the market from 2023 to 2033.
- China is expected to contribute 1% of the market share during the same period.
- India is projected to represent 5% of the market share from 2023 to 2033.
- Germany holds 2%, while the United Kingdom captures 5.2% market share over the next decade.
- Growth Drivers: Factors driving the market include increasing consumer awareness of gastrointestinal health, rising demand for over-the-counter treatments, and growing prevalence of acid reflux and related conditions.
- Future Projections: The antacids market is set to experience steady growth across key regions, particularly in developed economies, while emerging markets like China and India also contribute significantly to the market’s expansion.
Growing Market Interest: Explore Comprehensive Insights and Trends with Our Detailed Report!
Competitive Landscape
The antacid production market is highly fragmented, with numerous players vying for market share. These companies are adopting various strategies such as collaborations, partnerships, mergers and acquisitions, and the launch of new products to meet growing consumer demand and expand their customer base.
Recent Developments:
- On June 6, 2023, the US Food and Drug Administration (FDA) granted final approval to Zydus Lifesciences to market Famotidine tablets in 20 mg and 40 mg dosages.
- On February 22, 2023, GSK announced that its independent consumer healthcare business would operate under the new name, Haleon.
Additionally, Future Market Insights has tracked other significant developments in the antacid manufacturing sector, which are detailed in the full report.
Key Companies Profiled:
- Johnson and Johnson
- Sanofi S.A.
- Bayer AG
- Sun Pharmaceuticals Ltd
- Zydus Lifesciences
- Abbott Laboratories
- AstraZeneca plc
- Boehringer Ingelheim International GmbH
- Dr. Reddy’s Laboratories Ltd.
- GlaxoSmithKline plc
- Pfizer Inc.
- Procter & Gamble Company
- Reckitt Benckiser Group PLC
- Takeda Pharmaceutical Company Limited.
- F. Hoffmann-La Roche Ltd
Key Market Segments Covered in Antacids Industry Research
By Drug Class:
- Proton Pump Inhibitors
- H2 Antagonist
- Acid Neutralizers
- Pro-Motility Agents
- Anti-H.Pyrolic Drugs
- Prostaglandin Analogous
- Others
By Dosage form:
- Tablet
- Capsules
- Powder
- Liquid
- Others
By Route of Administration:
- Oral
- Injectable
By Indication:
- Gastroesophageal Reflux Disease
- Heartburn
- Peptic Ulcer
- Others
By Distribution channel:
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- The Middle East and Africa (MEA)
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
